Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients

NCT06754163 on ClinicalTrials.gov · last registry update 2026-04-28

A small phase 4 — 20 participants, against a typical 75. Due to report 31 July 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: St Andrew's Healthcare
Sponsor type: Other
Enrollment: 20
Started: 2025-01-01
Primary completion: 2027-07-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight

Conditions studied

Obesity and Obesity-related Medical Conditions · Psychiatric Disorders

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.